We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

127 hedge funds and large institutions have $713M invested in VanEck Pharmaceutical ETF in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 44 increasing their positions, 47 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

4% more capital invested

Capital invested by funds: $685M → $713M (+$28.7M)

0.9% less ownership

Funds ownership: 115.5% → 114.6% (-0.9%)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

6% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 47

2% less funds holding

Funds holding: 129 → 127 (-2)

93% less call options, than puts

Call options by funds: $3.59M | Put options by funds: $53.7M

Holders
127
Holders Change
-2
Holders Change %
-1.55%
% of All Funds
1.67%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
15
Increased
44
Reduced
47
Closed
16
Calls
$3.59M
Puts
$53.7M
Net Calls
-$50.2M
Net Calls Change
-$12M

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$57.1M
2
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
+$45.4M
3
RAM
Revere Asset Management
Texas
+$15.1M
4
Morgan Stanley
Morgan Stanley
New York
+$10.3M
5
Wells Fargo
Wells Fargo
California
+$8.54M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$75.8M
2
Jane Street
Jane Street
New York
-$26.2M
3
HW
Hamilton Wealth
California
-$11.7M
4
VV
Verity & Verity
South Carolina
-$11.6M
5
UBS Group
UBS Group
Switzerland
-$10.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCV
101
Banque Cantonale Vaudoise
Switzerland
$55K -$1.49K -17 -3%
ACA
102
Aptus Capital Advisors
Alabama
$47.7K +$350 +4 +0.8%
National Bank of Canada
103
National Bank of Canada
Quebec, Canada
$46.3K – – –
T
104
Tidemark
California
$46.2K +$2.19K +25 +5%
GWSG
105
GPS Wealth Strategies Group
Colorado
$41.5K – – –
ASN
106
Advisory Services Network
Georgia
$41.3K +$40K +457 New
IA
107
IFP Advisors
Florida
$39.6K +$13.4K +153 +54%
FFA
108
Farther Finance Advisors
California
$39.4K +$175 +2 +0.5%
Carson Wealth (CWM LLC)
109
Carson Wealth (CWM LLC)
Nebraska
$34K – – –
PS
110
Principal Securities
Iowa
$31.9K – – –
SS
111
SBI Securities
Japan
$29.2K +$3.42K +39 +14%
HPC
112
HM Payson & Co
Maine
$24.2K +$175 +2 +0.8%
CAL
113
Capital Analysts LLC
Pennsylvania
$21K – – –
CBT
114
CoreFirst Bank & Trust
Kansas
$18.1K – – –
TWC
115
TD Waterhouse Canada
Ontario, Canada
$16.1K – – –
GRP
116
Global Retirement Partners
California
$15.9K -$8.32K -95 -35%
OSAM
117
O'Shaughnessy Asset Management
Connecticut
$15.1K +$14.6K +167 New
NA
118
NewEdge Advisors
Louisiana
$9.22K – – –
AWM
119
Accredited Wealth Management
Kentucky
$9.04K -$7.01K -80 -80%
AT
120
Arlington Trust
Alabama
$7.68K – – –
AWM
121
Activest Wealth Management
Florida
$6.69K – – –
Comerica Bank
122
Comerica Bank
Texas
$5.6K -$32.2K -368 -86%
AIM
123
Anchor Investment Management
South Carolina
$5.24K – – –
RFP
124
Root Financial Partners
California
$1.81K +$1.75K +20 New
AssetMark Inc
125
AssetMark Inc
California
$1.35K -$88 -1 -6%
2 3 4
5
6

PPH Hedge Fund Activity: Q3 2025 in Review

127 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2025, worth a combined $713M — up 4.2% from $685M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PPH and 15 opened new positions — a net loss of 1 holder — while 47 trimmed existing stakes and 44 added.

The largest buyer was Citigroup, adding an estimated $57.1M. The largest seller was Goldman Sachs, cutting an estimated $75.8M.

  • 127 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2025, down from 129 in Q2 2025.
  • Funds reported $713M of VanEck Pharmaceutical ETF stock for Q3 2025, up 4.2% quarter-over-quarter.
  • 15 funds opened new VanEck Pharmaceutical ETF positions in Q3 2025 and 16 closed out, a net change of -1 holder.
  • The largest VanEck Pharmaceutical ETF buyer in Q3 2025 was Citigroup, an estimated $57.1M added.
  • The largest VanEck Pharmaceutical ETF seller in Q3 2025 was Goldman Sachs, an estimated $75.8M sold.

Based on aggregated 13F filings for Q3 2025.